Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Experimental Hematology & Oncology|January 8, 2026
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myelomaChenggong Tu, Arne Van der Vreken, Fien Meeus, et al.
Plos One|April 26, 2016
Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma PatientsLiesbeth Bieghs, Malene Brohus, Ida B Kristensen, et al.
Blood Cancer Journal|November 10, 2018
Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblastsSylvia Faict, Joséphine Muller, Kim De Veirman, et al.
Cell Death & Disease|February 13, 2021
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myelomaPatrick Nylund, Alba Atienza Párraga, Jakob Haglöf, et al.
Frontiers in Cell and Developmental Biology|June 27, 2022
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment ApproachPhilip Vlummens, Stefaan Verhulst, Kim De Veirman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllinMiguel Lemaire, Charlotte Fristedt, Prasoon Agarwal, et al.
Molecular Cancer Therapeutics|July 9, 2013
Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitroJinsong Hu, Els Van Valckenborgh, Dehui Xu, et al.
Pageof 10